BioSpace News Archive

Pictured: Close-up of a skin lesion in a patient w

Acelyrin’s Lead Asset Izokibep Fails in Late-Stage Hidradenitis Suppurativa Trial

Following a $540 million IPO in May, Acelyrin’s lead candidate izokibep failed to meet the primary endpoint in a Phase IIb/III study of patients with the chronic inflammatory skin condition.

September 12, 2023

·

2 min read

·

Tristan Manalac

U.S. and U.K. flags linked_Oleksii Liskonih, iStoc

Opinion: Building a Global Presence on Both Sides of the Pond

Vaccitech recently expanded from the U.K. to the U.S. CEO Bill Enright explains why.

September 12, 2023

·

4 min read

·

William “Bill” Enright

Business people networking/iStock, Hero Images

Biopharma Career Fairs Make a Powerful Comeback

In-person events have seen a flood of demand from students who want to meet biopharma employers personally, find employers in their area and scope out the industry scene.

September 12, 2023

·

3 min read

·

Andy Gooding-Call

Pictured: Money growth/iStock, RomoloTavani

Rome Secures J&J, BMS Investment to Boost Series B Total to $149M

A $72 million Series B extension includes new investors Johnson & Johnson and Bristol Myers Squibb to take Rome Therapeutics’ lead asset through to Phase I studies in autoimmune disease.

September 12, 2023

·

2 min read

·

Kate Goodwin

Pictured: Novartis headquarters in Basel, Switzerl

Business

Sandoz to Commercialize Samsung Bioepis’ Biosimilar to J&J’s Stelara

As the Novartis generics and biosimilars division nears its spin-off, Sandoz has signed a commercialization agreement with Samsung Bioepis, gaining rights to the latter’s Stelara biosimilar.

September 12, 2023

·

2 min read

·

Tristan Manalac

Pictured: Illustration depicting large layoffs/iSt

Business

2seventy to Lay Off 40% of Workforce, CEO to Depart in Reorganization

Citing a challenging macro environment, 2seventy bio is launching a sweeping strategic reorganization that will see 40% of its staff laid off and CEO Nick Leschly stepping down.

September 12, 2023

·

3 min read

·

Tristan Manalac

FDA Headquarters_Grandbrothers/Adobe Stock

Drug Development

FDA Questions Efficacy of Alnylam’s Drug in ATTR-CM Ahead of Adcomm Meeting

The agency’s briefing document found Phase III results investigating patisiran’s effects versus placebo were “small, of questionable clinical meaningfulness, and may not be detectable by patients.”

September 12, 2023

·

2 min read

·

Connor Lynch

Biotech Bay

Exai Bio Presents Data Further Validating its Liquid Biopsy Platform at the 2023 World Conference on Lung Cancer

Exai Bio announced non-small cell lung cancer data further validating that its novel RNA- and generative AI-based liquid biopsy platform detected early-stage disease with high accuracy.

September 12, 2023

·

4 min read

Insightec Receives CE Mark Approval to Treat Essential Tremor Patients’ Second Side, Expanding Treatment Options for People Living with Essential Tremor

Insightec, a global healthcare company specialising in MR-guided focused ultrasound, announced it has received additional CE mark approval for treatment of essential tremor using its Exablate Neuro platform.

September 12, 2023

·

4 min read

Salipro Biotech enters into research collaboration with Sumitomo Pharma to advance a drug discovery program

Swedish biotech company Salipro Biotech AB announced that it has entered into a research collaboration with Sumitomo Pharma Co., Ltd. to reveal the mechanism of action and pharmacological characterization of a drug candidate.

September 12, 2023

·

2 min read